Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) announced its participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 3:30 p.m. E.T. The event will be available via a live webcast on Sarepta's website and archived for 90 days. Sarepta is recognized for its innovations in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy (DMD), with over 40 programs underway across various therapeutic modalities including RNA and gene therapy.

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3^rd Annual HealthCONx Virtual Conference on Wednesday, Dec. 2, 2020 at 3:30 p.m. E.T.

The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.  

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.
Investors:
Ian Estepan, 617-274-4052, iestepan@sarepta.com

Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

FAQ

What is the date and time of the Sarepta Therapeutics fireside chat?

The Sarepta Therapeutics fireside chat is scheduled for December 2, 2020, at 3:30 p.m. E.T.

Where can I watch the Sarepta Therapeutics fireside chat?

You can watch the Sarepta Therapeutics fireside chat live on their website at www.sarepta.com, and it will be archived for 90 days.

What conference is Sarepta participating in on December 2, 2020?

Sarepta is participating in the Evercore ISI 3rd Annual HealthCONx Virtual Conference.

What is Sarepta Therapeutics known for?

Sarepta Therapeutics is known for its leadership in precision genetic medicine, particularly in the treatment of Duchenne muscular dystrophy (DMD).

How many programs does Sarepta have in development?

Sarepta Therapeutics has more than 40 programs in various stages of development focused on rare diseases.